CBIO Key Statistics, Chart & Performance
The current stock price of CBIO is 12.47 USD. In the past month the price decreased by -11.64%.
CBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.23 | 404.76B | ||
| AMGN | AMGEN INC | 15.15 | 178.43B | ||
| GILD | GILEAD SCIENCES INC | 15.24 | 154.90B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.61 | 117.21B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.14 | 52.83B | ||
| INSM | INSMED INC | N/A | 38.02B | ||
| NTRA | NATERA INC | N/A | 32.38B | ||
| BIIB | BIOGEN INC | 10.47 | 25.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.2 | 21.82B | ||
| INCY | INCYTE CORP | 15.55 | 19.60B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About CBIO
Company Profile
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Company Info
CRESCENT BIOPHARMA INC
300 Fifth Avenue
Waltham MASSACHUSETTS 94080 US
CEO: Nassim Usman
Employees: 4
Phone: 16174305595
CRESCENT BIOPHARMA INC / CBIO FAQ
Can you describe the business of CRESCENT BIOPHARMA INC?
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Can you provide the latest stock price for CRESCENT BIOPHARMA INC?
The current stock price of CBIO is 12.47 USD. The price increased by 0.81% in the last trading session.
What is the dividend status of CRESCENT BIOPHARMA INC?
CBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CBIO stock?
CBIO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does CRESCENT BIOPHARMA INC belong to?
CRESCENT BIOPHARMA INC (CBIO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming dividend date for CRESCENT BIOPHARMA INC?
The next ex-dividend date for CRESCENT BIOPHARMA INC (CBIO) is January 13, 2023.
CBIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CBIO.
CBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CBIO. While CBIO seems to be doing ok healthwise, there are quite some concerns on its profitability.
CBIO Financial Highlights
Over the last trailing twelve months CBIO reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 34.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -341.52% | ||
| ROE | -712.87% | ||
| Debt/Equity | 0 |